http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
殷載淳,鄭甲基,梁在憲,權鎭,吳贊鎬,全焄 又石大學校 1995 論文集 Vol.17 No.-
The purpose of this research was to investigate effect of water-soluble protein of Trichosanthes kirillowii(TKP) on the proliferation of human tumor cells. TKP inhibited the proliferation of HeLa cells and KHOS-NP cells. The inhibitory activity of doxorubicin on HeLa cells and its of mitomycin C on KHOS-NP cells were increased by the combination of TKP. TKP did not affect on the proliferation of Balb/c 3T3 cells, but inhibited the proliferation of mouse spleen cells and human lymphocyte at 1 ㎍/ml. These results suggest that TKP bas the cytotoxicity on HeLa and KHOS-NP cells, and increase the cytotoxicity of doxorubicin or mitomycin C.
3T3-L1 세포주에서 분비하는 인체 암세포 성장억제 단백질에 대한 연구
은재순,권진 우석대학교 의약품개발연구소 1996 藥學硏究誌 Vol.1 No.-
Ingibition of the growth of human cancer cells by proteins secreted from 3T3-L1 cells was investigated in the present study. The growth of human cancer cells was inhibited by co-culture with 3T3-L1 cells under 10% FBS and DME, GIT and serumless medium, respectively. The conditioned medium of cultured 3T3-L1 cells under serumless medium was concentrated 100-fold through an ultrafiltration cell with a 10,000 molecular weight cutoff at 4℃ under positive pressure using nitrogen (3T3-L1 EM). 3T3-L1 EM inhabited the growth of HrRa, Hep G2, KHOS-Np, A431 andMCF-7 cells. 3T3-L1 EM was purified with FPLC, DEAE-ion exchange chromatography and pheny-sepharose chromatography. The major protein of 3T3-L1 EM has a molecular weight of 66,000-69,000 in SDS-PAGE analysis. The results suggest that the inhibitory activity of 3T3-L1 EM appears to be due to some protein(m.w. 66,000-68,000) secreted by 3T3-L1 cells.
Soon-Jae Kweon,Soo-Hwan Shin,Sung-Hun Jo,Hyung-Joun Yoo IEEE 2014 IEEE TRANSACTIONS ON CIRCUITS AND SYSTEMS PART 2 E Vol.61 No.12
<P>A charge sampler-based reconfigurable high-order moving-average (MA) filter designed using a temporal MA method is proposed. The proposed filter has a higher gain than conventional MA filters. Moreover, the filter supports variable sizes and orders of MA. That is, the filter has a flexible frequency response by changing not only the sampling frequency but also the MA size (N) and MA order (M). The N and M are easily controlled by changing the clock patterns; therefore, the filter is suitable for multimode transceivers. To minimize the power consumption, inverter-based transconductance amplifiers are used. Here, our fabricated filter using a 65-nm CMOS technology supports MA (N = 2, M = 3) and MA (N = 3, M = 2) without changing the hardware.</P>
신규 플루오로퀴놀론계 DWP20367 의 흰쥐 및 개에서의 체내동태와 조직분포
심점순(Jeom Soon Shim),유영효(Young Hyo Yu),남권호(Kweon Ho Nam),박명환(Myung Hwan Park),공재양(Jae Yang Kong),조재열(Jae Youl Cho),한승희(Seung Hee Han),김병오(Byoung O Kim),정대영(Dae Young Jeong),이재욱(Jae Wook Lee),손호정(Ho Jun 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.3
The pharmacokinetics and tissue distribution of DWP20367 (1-cyclopropyl-6-fluoro-8-chloro-7-(2,7-diazabicyclo[3,3,0]oct-4-ene-7-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid), a novel fluoroquinolone, were examined in rats and beagle dogs after a single intravenous and oral administration. Analysis of DWP20367 in plasma, tissue, and urine was determined by both HPLC and microbiological assay (bioassay). The plasma concentration-time curves of the drug in rats and beagle dogs were biexponentially declined. The terminal halflife (t_(½β)) of the drug in rats was about 60.1 ±7.3 min (i.v.) and 61.3 ±12.4 min (p.o.) in bioassay, and 86.3 ±19.8 min (i.v.) and 50.9±14.9 min (p.o.) in HPLC. In beagle dogs, half-life of the drug determined by bioassay was about 121.8±6.2 min (i.v.) and 111.0±7.6 min (p.o.). The volume of distribution at steady-state (Vd_(ss)) was 243.8±74.1 ml/kg (bioassay) and 339.2±84.3 ml/kg (HPLC) in rats, and 1587.5±536.9 ml/kg (bioassay) in beagle dogs. The total body clearance (Cl₁,) of DWP20367 was 3.4±0.4 ml/min/kg (bioassay) and 2.4±0.4 ml/min/kg (HPLC) in rats, and 12.3±1.0 ml/min/kg (bioassay) in beagle dogs, respectively. The extent of bioavailability after oral administration was 89.1 %(bioassay) and 79.9% (HPLC) in rats, and 78.7% (bioassay) in beagle dogs. Urinary recovery (24-h) assayed by bioassay was 0.7% (p.o.) and 1.2% (i.v.) in rats, and 0.8% (p.o.) and 1.0% (i.v.) in beagle dogs. In rats, 24-h fecal recovery determined by bioassay was 11.2% (p.o.) and 0.1% (i.v.). Rat and human serum protein binding ratios at 2 ㎍/ml were about 90∼91%. This drug determined by bioassay was also distributed by the order of liver, kidney, lung, heart, spleen and muscle 30 min after oral administration.